BioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests
BioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests
BioAffinity Technologies看到医生处方CyPath肺部检测的增长加速
Sales of CyPath Lung tests, onboarding of pathology practices ahead of forecasts
超越预期的CyPath肺部检测销售，病理实践的接入
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported 139% growth in the number of pulmonology practices and physicians offering CyPath Lung to patients since Jan. 1, 2024. CyPath Lung is a noninvasive test to detect early-stage lung cancer.
生物技术公司bioAffinity Technologies, Inc.（纳斯达克股票代码：BIAF、BIAFW）专注于早期癌症和肺病的非侵入性检测需求，今天报告称，自2024年1月1日以来，使用CyPath肺部检测的肺部科学实践和医生数量增长了139%。CyPath Lung是一种非侵入性检测方法，用于检测早期肺癌。